AI assistant
ADDvise Group B — M&A Activity 2023
May 8, 2023
8222_rns_2023-05-08_a3d9f935-992e-4ff2-ae91-abfe3df0863e.pdf
M&A Activity
Open in viewerOpens in your device viewer
ADDvise
PRESS RELEASE
Stockholm May 8, 2023
ADDvise signs Letter of Intent to acquire Kolplast CI S.A.
ADDvise has signed a Letter of Intent with the shareholders of Kolplast CI S.A. ("Kolplast") regarding an acquisition of all shares in Kolplast.
Kolplast is a Brazilian manufacturer of MedTech equipment based in São Paulo, Brazil. The company produces disposable medical devices, MedTech equipment, laboratory equipment, and liquid-based cytology products. The company is the market leader in Brazil with over 8,000 active clients. Several of the company's products are registered for sale in the US and Europe.
The company's revenue for the full year 2022 amounted to BRL 100.3 million with an adjusted EBITDA of BRL 28.1 million, corresponding to an adjusted EBITDA margin of 28 percent.
The purchase price for Kolplast amounts to an initial payment of BRL 160 million, and three potential earn-outs of BRL 50 million in total.
The acquisition will be financed with own funds and loans. ADDvise assesses that the acquisition will have a positive impact on ADDvise earnings per share during the financial year 2023.
The acquisition is subject to a due diligence and that the parties agree to enter into a share purchase agreement. The share purchase agreement and completion of the acquisition is scheduled to be completed during the second half of 2023.
For further information, please contact:
Rikard Akhtarzand, CEO
+46 765-25 90 71
[email protected]
Hanna Myhrman, General Counsel
+46 709-82 92 23
[email protected]
Sid 1/2
ADDvise
Important information
This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on May 8, 2023, at 06:30 CEST.
About ADDvise Group
ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The Group consists of two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expanding the business - both geographically and product-wise. ADDvise Group's shares are listed on Nasdaq First North Premier Growth Market and Mangold Fondkommission AB, +46 8 503 015 50, [email protected], is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.
Sid 2/2